There is no difference between postoperative chemotherapy and no chemotherapy for early pancreatic cancer, but the difference between doing or not doing chemotherapy for middle and late pancreatic cancer is that it will affect the chance of recurrence and the survival time of patients. Pancreatic cancer is a relatively common malignant tumor in clinic, for patients who cannot undergo surgical resection, chemotherapy can be considered, chemotherapy is one of the important means of treating pancreatic cancer, which can control the progress of the disease and prolong the survival of patients. Domestic guidelines point out that: postoperative adjuvant chemotherapy for pancreatic cancer is effective in preventing or delaying tumor recurrence, and patients after radical surgery without contraindications should undergo adjuvant chemotherapy. Among them, neoadjuvant chemotherapy can help to improve the R0 resection rate of patients with resectable pancreatic cancer at the junction and improve the prognosis of patients; some patients with locally progressive pancreatic cancer can get the chance to have surgery to improve the prognosis through conversion therapy. Adjuvant chemotherapy should be performed for all postoperative pancreatic cancers, and it should be started within 8 weeks after surgery as far as possible, and the preferred combination chemotherapy regimen is based on the patients’ physical status; patients with unresectable advanced pancreatic cancer should be actively treated with systemic therapy. Studies have shown that chemotherapy can significantly improve patients’ prognosis (recurrence, metastasis and survival time, etc.). If pancreatic cancer is suspected or diagnosed, it is recommended to go to a regular hospital for comprehensive assessment of the condition and follow the doctor’s instructions to cooperate with the treatment, so as not to delay the condition.